US 11,667,712 B2
Materials and methods for modulating t cell mediated immunity
Rajkumar Ganesan, Blue Bell, PA (US); Iqbal S. Grewal, Newtown, PA (US); and Sanjaya Singh, Blue Bell, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on May 7, 2020, as Appl. No. 16/869,401.
Claims priority of provisional application 62/844,966, filed on May 8, 2019.
Claims priority of provisional application 62/844,976, filed on May 8, 2019.
Claims priority of provisional application 62/844,959, filed on May 8, 2019.
Claims priority of provisional application 62/844,970, filed on May 8, 2019.
Claims priority of provisional application 62/844,995, filed on May 8, 2019.
Prior Publication US 2021/0032338 A1, Feb. 4, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 38/17 (2006.01)
CPC C07K 16/2809 (2013.01) [A61K 38/1709 (2013.01); C07K 16/2866 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01)] 41 Claims
 
1. An antibody that binds to T Cell Receptor Gamma Variable 9 (TRGV9), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the antibody comprises: (i) a VH comprising a VH complementarity determining region (CDR) 1 having the amino acid sequence of SEQ ID NO: 1, a VH CDR2 having the amino acid sequence of SEQ ID NO:2, and a VH CDR3 having the amino acid sequence of SEQ ID NO:31, SEQ ID NO:32 or SEQ ID NO:33; and (ii) a VL comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:4, a VL CDR2 having the amino acid sequence of SEQ ID NO: 5, and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.